Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 25:8:372.
doi: 10.1186/s13104-015-1344-0.

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision

Susan Creary  1 , Susan Zickmund  2 , Diana Ross  3 , Lakshmanan Krishnamurti  4 , Debra L Bogen  5
Affiliations

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision

Susan Creary et al. BMC Res Notes. .

Abstract

Background: Hydroxyurea (HU) is underutilized in children with sickle cell disease (SCD) because caregivers frequently decline HU when it is offered. This study explores what impacts this decision.

Results: Caregivers of children with clinically severe SCD whose children were offered HU previously were interviewed. We used a qualitative analytical approach to analyze their telephone interview transcripts. Caregivers who chose HU (n = 9) reported their children had severe SCD, sought detailed information about HU, and accepted HU as a preventative therapy. In contrast, caregivers who did not choose HU (n = 10) did not perceive their children as having severe SCD and did not question their child's provider about HU.

Conclusions: This study identifies specific areas that providers should address to when they discuss HU with families so that they can make informed decisions. Our study also uncovered factors that are important to consider when designing future interventions to improve hydroxyurea acceptance and when developing decision-aid tools to assist caregivers of children with SCD who are considering disease modifying therapies.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The semi-structured interview guide
See this image and copyright information in PMC

References

    1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Eng J Med. 1994;330:1639–1644. doi: 10.1056/NEJM199406093302303. - DOI - PubMed
    1. National Heart, Lung, and Blood Institute, Disease and Conditions Index: sickle cell anemia: who is at risk? http://www.nhlbi.nih.gov/health/health-topics/topics/sca/atrisk.html. Published September 28, 2012. Accessed Nov 7 2012.
    1. Hankins J, Hinds P, Day S, et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr Blood Cancer. 2007;48:705–710. doi: 10.1002/pbc.20903. - DOI - PubMed
    1. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG) Lancet. 2011;377:1663–1672. doi: 10.1016/S0140-6736(11)60355-3. - DOI - PMC - PubMed
    1. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106:2269–2275. doi: 10.1182/blood-2004-12-4973. - DOI - PMC - PubMed

Publication types